Induction of methionine sulfoxide reductase activity by pergolide, pergolide sulfoxide, and S-adenosyl-methionine in neuronal cells

Neuroscience Letters

Volumn 533, Issue 1, 2013, Pages 86-89

  Franklin, Jade M ^a   Carrasco, Gonzalo A ^a   Moskovitz, Jackob ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Antioxidants; Oxidative stress; Pergolide; Post translational modification; S adenosyl methionine; Signal transduction

Indexed keywords

METHIONINE SULFOXIDE REDUCTASE; PERGOLIDE; PERGOLIDE SULFOXIDE; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; CELL PROTECTION; ENZYME ACTIVITY; MOLECULE; NERVE CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE; ANIMALS; CELL LINE; DOPAMINE; ENZYME INDUCTION; ETHIONINE; METHIONINE SULFOXIDE REDUCTASES; NEURONS; PERGOLIDE; RATS; RECEPTORS, CANNABINOID; SEROTONIN;

EID: 84871678912     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.11.017     Document Type: Article

References (22)

1. Baseman D.G., O'Suilleabhain P.E., Reimold S.C., Laskar S.R., Baseman J.G., Dewey R.B. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004, 63:301-304.
2. Cavallaro R.A., Fuso A., Nicolia V., Scarpa S. S-adenosylmethionine prevents oxidative stress and modulates glutathione metabolism in TgCRND8 mice fed a B-vitamin deficient diet. Journal of Alzheimer's Disease 2010, 20:997-1002.
3. Chan A., Shea T.B. Effects of dietary supplementation with N-acetyl cysteine, acetyl-l-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4. Neuromolecular Medicine 2007, 9:264-269.
4. Fuller R.W., Clemens J.A. Pergolide: a dopamine agonist at both D1 and D2 receptors. Life Sciences 1991, 49:925-930.
5. Gabbita S.P., Aksenov M.Y., Lovell M.A., Markesbery W.R. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. Journal of Neurochemistry 1999, 73:1660-1666.
6. Jung B., Lee E.H., Chung W.S., Lee S.J., Shin S.H., Joo S.H., Kim S.K., Lee J.H. Increased viability of PC12 cells exposed to amyloid-beta peptide by transduction with human TAT-methionine sulfoxide reductase. Neuroreport 2003, 14:2349-2353.
7. Kantorow M., Hawse J.R., Cowell T.L., Benhamed S., Pizarro G.O., Reddy V.N., Hejtmancik J.F. Methionine sulfoxide reductase A is important for lens cell viability and resistance to oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:9654-9659.
8. Kvernmo T., Härtter S., Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clinical Therapeutics 2006, 28:1065-1078.
9. Moskovitz J., Flescher E., Berlett B.S., Azare J., Poston J.M., Stadtman E.R. Overexpression of peptide-methionine sulfoxide reductase in Saccharomyces cerevisiae and human T cells provides them with high resistance to oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14071-14075.
10. Moskovitz J., Jenkins M.A., Gilbert D.J., Copeland N.G., Jursky F., Weissbach H., Brot N. Chromosomal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:3205-3208.
11. Moskovitz J., Maiti P., Lopes D.H., Oien D.B., Attar A., Liu T., Mittal S., Hayes J., Bitan G. Induction of methionine-sulfoxide reductases protects neurons from amyloid β-protein insults in vitro and in vivo. Biochemistry 2011, 50:10687-10697.
12. Moskovitz J., Poston J.M., Berlett B.S., Nosworthy N.J., Szczepanowski R., Stadtman E.R. Identification and characterization of a putative active site for peptide methionine sulfoxide reductase (MsrA) and its substrate stereospecificity. The Journal of Biological Chemistry 2000, 275:14167-14172.
13. Moskovitz J., Stadtman E.R. Selenium-deficient diet enhances protein oxidation and affects methionine sulfoxide reductase (MsrB) protein level in certain mouse tissues. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:7486-7490.
14. Oien D.B., Ortiz A.N., Rittel A.G., Dobrowsky R.T., Johnson M.A., Levant B., Fowler S.C., Moskovitz J. Dopamine D(2) receptor function is compromised in the brain of the methionine sulfoxide reductase A knockout mouse. Journal of Neurochemistry 2010, 114:51-61.
15. Oien D.B., Moskovitz J. Substrates of the methionine sulfoxide reductase system and their physiological relevance. Current Topics in Developmental Biology 2008, 80:93-133.
16. Pal R.R., Oien D.B., Ersen F.Y., Moskovitz J. Elevated levels of brain-pathologies associated with neurodegenerative diseases in the methionine sulfoxide reductase A knockout mouse. Experimental Brain Research 2007, 180:765-774.
17. Schade R., Andersohn F., Suissa S., Haverkamp W., Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine 2007, 356:29-38.
18. Smith R.V., Davis P.J., Kerr K.M. Microbial transformations of pergolide to pergolide sulfoxide and pergolide sulfone. Journal of Pharmaceutical Sciences 1983, 72:733-736.
19. Stadtman E.R., Moskovitz J., Berlett B.S., Levine R.L. Cyclic oxidation and reduction of protein methionine residues is an important antioxidant mechanism. Molecular and Cellular Biochemistry 2002, 234-235:3-9.
20. Van Camp G., Flamez A., Cosyns B., Weytjens C., Muyldermans L., Van Zandijcke M., De Sutter J., Santens P., Decoodt P., Moerman C., Schoors D. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004, 363:1179-1183.
21. Villalobos M.A., De La Cruz J.P., Cuerda M.A., Ortiz P., Smith-Agreda J.M., Sánchez De La Cuesta F. Effect of S-adenosyl-l-methionine on rat brain oxidative stress damage in a combined model of permanent focal ischemia and global ischemia-reperfusion. Brain Research 2000, 883:31-40.
22. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine 2007, 356:39-46.